NASD · Healthcare · Biotechnology · USA
Immunovant Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
Immunovant is a clinical-stage immunology company developing IMVT-1402, an FcRn inhibitor for autoimmune diseases driven by pathogenic IgG antibodies. The company is conducting clinical trials in six indications including Graves' disease, rheumatoid arthritis, myasthenia gravis, CIDP, Sjögren's disease, and cutaneous lupus erythematosus.
From its FY2026 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Immunovant Inc stock.
Not valued: We cannot value this company yet.
17 more funds hold it; the full list is part of the paid plan.
129 more in this industry show a wider margin of safety.
We do not publish a verdict on IMVT yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.
We do not publish one (as of the 2026-11-17 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.